ClassID:

96693

C07K5/06095 - CPC Classification

Classification description:

Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links; Dipeptides with the first amino acid being basic Arg-amino acid

Recent Application in this class:
#1
20250171495
2025-05-29

MUTLI-TARGETED SERINE PROTEASE INHIBITORS FOR TREATMENT OF CANCER AND VIRAL INFECTION

#2
20250122238
2025-04-17

CRYSTALLINE DIPEPTIDES USEFUL IN THE SYNTHESIS OF ELAMIPRETIDE

#3
20250051389
2025-02-13

AROMATIC-CATIONIC PEPTIDES AND USES OF SAME

#4
20250002530
2025-01-02

AROMATIC-CATIONIC PEPTIDES AND USES OF SAME

#5
20240392319
2024-11-28

TRANSFECTION COMPLEXES AND METHODS OF USING THE SAME

#6
20240368225
2024-11-07

SELECTIVE SMALL MOLECULE AGONISTS AND PARTIAL AGONISTS OF TRK RECEPTORS

#7
20240350677
2024-10-24

PSMA-TARGETED NIR DYES AND THEIR USES

#8
20240084068
2024-03-14

POLYMER COMPOUND COMPRISING PENDENT PEPTIDES, METHOD FOR PREPARING SAME AND USES THEREOF

#9
20240059734
2024-02-22

MITOCHONDRIA-TARGETING PEPTIDES

#10
20230203093
2023-06-29

Crystalline dipeptides useful in the synthesis of elamipretide

#11
20230146515
2023-05-11

Mitochondria-targeting peptides

#12
20220169676
2022-06-02

INHIBITORS OF GROWTH FACTOR ACTIVATION ENZYMES

#13
20220167610
2022-06-02

DMSO-FREE CRYOPRESERVATION SOLUTION AND PREPARATION METHOD AND USE THEREOF

#14
20220144909
2022-05-12

CSF1R-BASED CHIMERIC PROTEINS

#15
20220112237
2022-04-14

AMINO ACID COMPOSITION HAVING CO-AMORPHOUS STRUCTURE

#16
20220105205
2022-04-07

PSMA-TARGETED NIR DYES AND THEIR USES

#17
20220090141
2022-03-24

Transfection complexes and methods of using the same

#18
20210393855
2021-12-23

NEW HYDROGELS HAVING A SILYLATED STRUCTURE, AND METHOD FOR OBTAINING SAME

#19
20210292274
2021-09-23

Crystalline dipeptides useful in the synthesis of elamipretide

#20
20210261610
2021-08-26

METHOD FOR PRODUCING AMIDE

#21
20210130402
2021-05-06

AROMATIC-CATIONIC PEPTIDES AND USES OF SAME

#22
20210046194
2021-02-18

PSMA-targeted NIR dyes and their uses

#23
20210040149
2021-02-11

Aromatic-cationic peptides and uses of same

#24
20210040039
2021-02-11

NMDA ANTAGONIST PRODRUGS

#25
20200323947
2020-10-15

Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof

#26
20200283476
2020-09-10

Crystalline dipeptides useful in the synthesis of elamipretide

#27
20200123214
2020-04-23

CSF1R-based chimeric proteins

#28
20190382466
2019-12-19

CSF1R-CD40L chimeric proteins

#29
20190202861
2019-07-04

N-carboxyanhydride-based-scale synthesis of elamipretide

#30
20190169249
2019-06-06

CSF1R-based chimeric proteins

#31
20190152914
2019-05-23

NMDA antagonist prodrugs

#32
20190151480
2019-05-23

PSMA-targeted NIR dyes and their uses

#33
20190106458
2019-04-11

AROMATIC-CATIONIC PEPTIDES AND USES OF SAME

#34
20190023738
2019-01-24

THERAPEUTIC COMPOSITIONS INCLUDING PHENAZINE-3-ONE AND PHENOTHIAZINE-3-ONE DERIVATIVES AND USES THEREOF

#35
20180362579
2018-12-20

AROMATIC-CATIONIC PEPTIDES AND USES OF SAME

#36
20180356415
2018-12-13

FLUOROUS COMPOUND, METHOD OF PREPARING FLUOROUS TAGGED PROTEIN, AND METHOD OF IMMOBILIZING PROTEIN

#37
20180354989
2018-12-13

Antimicrobial peptidomimetics

#38
20180340188
2018-11-29

Transfection complexes and methods of using the same

#39
20180200408
2018-07-19

NEW HYDROGELS HAVING A SILYLATED STRUCTURE, AND METHOD FOR OBTAINING SAME

#40
20180186833
2018-07-05

Selective cysteine protease inhibitors and uses thereof

#41
20180066015
2018-03-08

Inhibitors of growth factor activation enzymes

#42
20180057529
2018-03-01

Pro-Amb reverse turn restricted bioactive peptide analogues

#43
20180037550
2018-02-08

NMDA antagonist prodrugs

#44
20170319717
2017-11-09

PSMA—targeted NIR dyes and their uses

#45
20170314023
2017-11-02

Matriptase inhibitors and uses thereof against orthomyxoviridae infections

#46
20170281801
2017-10-05

PSMA-targeted NIR dyes and their uses

#47
20170267718
2017-09-21

Tripeptide compound, preparation method therefor, and application thereof

#48
20170260231
2017-09-14

Substrates and inhibitors of prolyl oligopeptidase and methods of use thereof

#49
20170196933
2017-07-13

Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof

#50
20170066719
2017-03-09

PSMA-targeted NIR dyes and their uses

#51
20170065729
2017-03-09

PSMA-targeted NIR dyes and their uses

#52
20160333048
2016-11-17

Antimicrobial peptidomimetics

#53
20160280647
2016-09-29

NMDA antagonist prodrugs

#54
20160207958
2016-07-21

Method for producing dipeptide derivative containing disubstituted amino acid residue

#55
20160097052
2016-04-07

Matriptase inhibitors and uses thereof against orthomyxoviridae infections

#56
20160068788
2016-03-10

Liquid automatic dish washing detergent compositions

#57
20160002291
2016-01-07

Active Agent Prodrugs with Heterocyclic Linkers

#58
20150307549
2015-10-29

AGENT FOR PREVENTING ARTERIOSCLEROSIS, AGENT FOR SUPPRESSING VASCULAR INTIMAL THICKENING AND AGENT FOR IMPROVING VASCULAR ENDOTHELIAL FUNCTION

#59
20150175663
2015-06-25

Process for producing self-assembling peptide derivatives

#60
20150175662
2015-06-25

Peptides and use thereof

#61
20150119330
2015-04-30

Substrates and inhibitors of prolyl oligopeptidase and methods of use

#62
20150065437
2015-03-05

AROMATIC-CATIONIC PEPTIDES AND USES OF SAME

#63
20150031854
2015-01-29

Derivatives of hemin with antibacterial and antiviral activity

#64
20150011730
2015-01-08

Cyclin based inhibitors of CDK2 and CDK4

#65
20140336098
2014-11-13

Stabilized subtilisin composition

#66
20140288268
2014-09-25

Method of producing peptide

#67
20140243274
2014-08-28

Peptide derivatives for treatment, prevention or alleviation of a condition associated with bone loss or low bone density or to inhibit osteoclast differentiation and stimulation

#68
20140187479
2014-07-03

Boropeptide inhibitors of enteropeptidase and their uses in treatment of obesity, overweight and/or diseases associated with an abnormal fat metabolism

#69
20140086936
2014-03-27

Matriptase inhibitors and uses thereof against orthomyxoviridae infections

#70
20140038903
2014-02-06

Selective cysteine protease inhibitors and uses thereof

#71
20130059799
2013-03-07

AROMATIC-CATIONIC PEPTIDES AND USES OF SAME

#72
20130023475
2013-01-24

C-Met receptor regulation by angiotensin IV (AT4) receptor ligands

#73
20120301490
2012-11-29

Immunoconjugates, compositions for making them, and methods of making and use

#74
20120270774
2012-10-25

MACROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND METHODS FOR PREVENTING OR TREATING HIV INFECTION

#75
20120214732
2012-08-23

Inhibitors of the trypsin-like site of the proteasome and methods of use thereof

#76
20120108520
2012-05-03

Method of treating tumors

#77
20120108515
2012-05-03

Peptide derivatives for treatment, prevention or alleviation of a condition associated with bone loss or low bone density or to inhibit osteoclast differentiation and stimulation

#78
20120108499
2012-05-03

PEPTOID COMPOUNDS

#79
20120045474
2012-02-23

Substrate peptide sequences for plague plasminogen activator and uses thereof

#80
20120035096
2012-02-09

AGENT FOR PREVENTING ARTERIOSCLEROSIS, AGENT FOR SUPPRESSING VASCULAR INTIMAL THICKENING AND AGENT FOR IMPROVING VASCULAR ENDOTHELIAL FUNCTION

#81
20110262359
2011-10-27

COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF

#82
20110250153
2011-10-13

Oligomeric biosurfactants in dermatocosmetic compositions

#83
20110224154
2011-09-15

Peptide derivative and composition for promoting tear secretion comprising the same

#84
20110082281
2011-04-07

Casein hydrolyzate, process for producing the same and use thereof

#85
20110071040
2011-03-24

Mass- and property-tuned variable mass labeling reagents and analytical methods for simultaneous peptide sequencing and multiplexed protein quantification using thereof

#86
20110039849
2011-02-17

5-substituted-2-imino-thiazolidinone compounds and their use as inhibitors of bacterial infection

#87
20100330700
2010-12-30

Substrate for assaying β-glucan and/or endotoxin and assay method

#88
20100311690
2010-12-09

BOROPEPTIDE INHIBITORS OF ENTEROPEPTIDASE AND THEIR USES IN TREATMENT OF OBESITY, OVERWEIGHT AND/OR DISEASES ASSOCIATED WITH AN ABNORMAL FAT METABOLISM

#89
20100304363
2010-12-02

PEPTIDE COMPOUNDS FOR DETECTING OR INHIBITING SARS CORONAVIRUS AND APPLICATION THEREOF

#90
20100267621
2010-10-21

Antimicrobial compounds and formulations

#91
20100247648
2010-09-30

ANTIMICROBIAL COMPOUNDS

#92
20100240598
2010-09-23

PEPTIDES AND PEPTIDE MIMETICS TO INHIBIT THE ONSET AND/OR PROGRESSION OF FIBROTIC AND/OR PRE-FIBROTIC PATHOLOGIES

#93
20100227825
2010-09-09

PEPTIDES AND PEPTIDE MIMETICS TO TREAT CANCER

#94
20100167995
2010-07-01

PEPTOID COMPOUNDS

#95
20100139716
2010-06-10

Prober cleaning block assembly

#96
20090299036
2009-12-03

AGENT FOR PREVENTING ARTERIOSCLEROSIS, AGENT FOR SUPPRESSING VASCULAR INTIMAL THICKENING AND AGENT FOR IMPROVING VASCULAR ENDOTHELIAL FUNCTION

#97
20090286763
2009-11-19

AMINO ACID DERIVED PRODRUGS OF PROPOFOL, COMPOSITIONS AND USES THEREOF

#98
20090264620
2009-10-22

N-Methylation of amino acids

#99
20090118198
2009-05-07

Peptide derivatives useful as antimicrobial agents and for treating wounds

#100
20090069538
2009-03-12

Method of producing peptide

#101
20090069248
2009-03-12

Substrate peptide sequences for plague plasminogen activator and uses thereof

#102
20090012306
2009-01-08

Cationic amino acid type lipid

#103
20080300191
2008-12-04

Protease inhibitors for coronaviruses and SARS-CoV and the use thereof

#104
20080293634
2008-11-27

C-Met receptor regulation by angiotensin IV (AT) receptor ligands

#105
20070299014
2007-12-27

Casein hydrolyzate, process for producing the same and use thereof

#106
20070231284
2007-10-04

α-MSH-antagonist dipeptide conjugates

#107
20070129313
2007-06-07

Sulfonylamino-peptidomimetics active on the somatostatin receptor subtypes 4 (sstr4) and 1 (sstr1)

#108
20070122451
2007-05-31

Biogically non-degradable peptides, angiostensin converting enzyme inhibitor, drug and functional food

#109
20070111927
2007-05-17

Peptoid compounds

#110
20070004644
2007-01-04

Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia

#111
20060148901
2006-07-06

Acylated 4-amidino- and -4-guanidinobenzylamines for inhibition of plasma kallikrein

#112
20060116327
2006-06-01

Antimicrobial compounds

#113
20060100160
2006-05-11

Amino acid derived prodrugs of propofol, compositions and uses thereof

#114
20060068457
2006-03-30

Substrates for TAFI (A)

#115
20060009396
2006-01-12

Heteroaryl peptidomimetics as thrombin receptor antagonists

#116
20050095248
2005-05-05

Suppression of immune response via inhibition of cathepsin S

#117
20050080010
2005-04-14

Suppression of immune response via inhibition of cathepsin S

#118
20050043509
2005-02-24

Peptoid compounds